QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
NYSEAMERICAN:IBIO

iBio Stock Forecast, Price & News

$0.48
0.00 (0.00%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.47
$0.49
50-Day Range
N/A
52-Week Range
$0.47
$2.83
Volume
2.11 million shs
Average Volume
1.81 million shs
Market Capitalization
$104.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-6.01
30 days | 90 days | 365 days | Advanced Chart
Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.


iBio logo

About iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The firm operates through the Biopharmaceuticals and Bioprocessing segments. The company was founded by Robert B. Kay on April 15, 1993 and is headquartered in Bryan, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
47
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.37 million
Book Value
$0.50 per share

Profitability

Net Income
$-23.21 million
Net Margins
-1,133.19%
Pretax Margin
-1,133.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
216,149,000
Market Cap
$104.62 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/19/2022
Next Earnings (Estimated)
2/14/2022
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio
or view top-rated stocks.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for iBio
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative net margin of 1,133.19% and a negative trailing twelve-month return on equity of 33.06%.
View iBio's earnings history
.

When did iBio's stock split? How did iBio's stock split work?

iBio shares reverse split on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

2 brokerages have issued 12-month price objectives for iBio's shares. Their forecasts range from $1.50 to $3.00. On average, they anticipate iBio's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 368.8% from the stock's current price.
View analysts' price targets for iBio
or view top-rated stocks among Wall Street analysts.

Who are iBio's key executives?

iBio's management team includes the following people:
  • Thomas F. Isett, Executive Chairman, President & CEO
  • Randy J. Maddux, Chief Operating Officer
  • Robert M. Lutz, Chief Financial & Business Officer
  • Martin B. Brenner, Chief Scientific Officer
  • James Abbey, Vice President-Strategic Business Development

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio
.

Which major investors are selling iBio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for iBio
or view top insider-selling stocks.

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.48.

How much money does iBio make?

iBio has a market capitalization of $104.62 million and generates $2.37 million in revenue each year. The biotechnology company earns $-23.21 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does iBio have?

iBio employs 47 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

Where are iBio's headquarters?

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at (302) 355-0650, via email at [email protected], or via fax at 302-356-1173.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.